In 2016, nivolumab and pembrolizumab, which are anti-programmed cell death 1 (anti-PD-1) antibody, were approved by the US Food and Drug Administration (FDA) for HNSCC treatment. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.